Last reviewed · How we verify
NCT05737004
Effects of Prostate Cancer on Brain Function
trial testing functional magnetic resonance imaging examination、Zung Self Rating Anxiety Scale and Beck Depression Inventory-II in Prostate Cancer in 250 participants. Status unknown.
12 February 2024
Quick facts
| Lead sponsor | Shanghai East Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 250 |
| Start date | 13 April 2023 |
| Primary completion | 12 February 2024 |
| Estimated completion | 1 April 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- functional magnetic resonance imaging examination、Zung Self Rating Anxiety Scale and Beck Depression Inventory-II
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
Sponsor
Shanghai East Hospital
Who can join
Adults 18 to 80, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To explore whether the patients with prostate cancer have functional changes in specific brain areas and changes in psychological and mental characteristics compared with the patients without prostate cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05737004
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Shanghai East Hospital trials
Trials by the same sponsor.
- NCT07519161 — Pharmacological Intervention to Prevent NOAF After TAVR · NA · not yet recruiting
- NCT07516223 — MRI-Assisted Guidance for Non-Essential Tissue Sampling · NA · not yet recruiting
- NCT07279259 — Thrombolysis in Early Acute Ischemic Stroke Trial-Blood Pressure Management · Phase 2 · recruiting
- NCT07294495 — Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Tr · NA · not yet recruiting
- NCT07290816 — Effect of Non-invasive Neuromodulation on the Quality of Intestinal Cleansing · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05737004 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai East Hospital
- Last refreshed: 19 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05737004.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing